10.29.15
Gilead
3Q Revenues: $8.3 billion (+37%)
3Q Earnings: $4.6 billion (+69%)
YTD Revenues: $24.1 billion (+37%)
YTD Earnings: $13.4 billion (+56%)
Comments: Antiviral product sales were $7.7 billion in the quarter, up 40% primarily driven by Harvoni sales of $3.3 billion, partially offset by a decrease in sales of Sovaldi (-48% to $1.5 billion) as a result of uptake in Harvoni. Atripla sales were $818 million in the quarter, down 9%. Stribild sales were $511 million, up 56%. Complera sales were $360 million, up 9%. Viread sales were $297 million, up 8%. Letairis sales were $181 million, up 24%. Ranexa sales were up 22% to $161 million. R&D expenses were $743 million in the quarter, up 18%.
3Q Revenues: $8.3 billion (+37%)
3Q Earnings: $4.6 billion (+69%)
YTD Revenues: $24.1 billion (+37%)
YTD Earnings: $13.4 billion (+56%)
Comments: Antiviral product sales were $7.7 billion in the quarter, up 40% primarily driven by Harvoni sales of $3.3 billion, partially offset by a decrease in sales of Sovaldi (-48% to $1.5 billion) as a result of uptake in Harvoni. Atripla sales were $818 million in the quarter, down 9%. Stribild sales were $511 million, up 56%. Complera sales were $360 million, up 9%. Viread sales were $297 million, up 8%. Letairis sales were $181 million, up 24%. Ranexa sales were up 22% to $161 million. R&D expenses were $743 million in the quarter, up 18%.
